Department of Cardiology, Institute CARDIOMET, University Hospital of Toulouse, 31059 Toulouse, France.
Faculty of Medicine, Holy Spirit University of Kaslik, Kaslik 446, Lebanon.
Cells. 2022 May 12;11(10):1620. doi: 10.3390/cells11101620.
Transplantation of mesenchymal stem cells (MSCs) in the setting of cardiovascular disease, such as heart failure, cardiomyopathy and ischemic heart disease, has been associated with good clinical outcomes in several trials. A reduction in left ventricular remodeling, myocardial fibrosis and scar size, an improvement in endothelial dysfunction and prolonged cardiomyocytes survival were reported. The regenerative capacity, in addition to the pro-angiogenic, anti-apoptotic and anti-inflammatory effects represent the main target properties of these cells. Herein, we review the different preconditioning methods of MSCs (hypoxia, chemical and pharmacological agents) and the novel approaches (genetically modified MSCs, MSC-derived exosomes and engineered cardiac patches) suggested to optimize the efficacy of MSC therapy.
间充质干细胞（MSCs）移植在心脑血管疾病如心力衰竭、心肌病和缺血性心脏病的治疗中，与多项临床试验的良好临床结局相关。研究报道，MSCs 移植可减少左心室重构、心肌纤维化和瘢痕面积，改善内皮功能障碍并延长心肌细胞的存活。除了促血管生成、抗细胞凋亡和抗炎作用外，其再生能力是这些细胞的主要靶向特性。在此，我们综述了不同的 MSCs 预处理方法（低氧、化学和药物制剂）和新方法（基因修饰的 MSCs、MSC 衍生的外泌体和工程化心脏贴片），这些方法旨在优化 MSC 治疗的疗效。
